Literature DB >> 26767008

Surgical treatment for pulmonary pleomorphic carcinoma: A retrospective study of 60 patients.

Chunyu Ji1, Chenxi Zhong1, Wentao Fang1, Heng Zhao1.   

Abstract

BACKGROUND: Pleomorphic carcinoma is a rare epithelial malignant tumor. Because the clinical characteristics and behavior of the disease remain unclear, we investigated the clinicopathological findings and prognosis of 60 patients with pleomorphic carcinoma.
METHODS: The clinicopathological characteristics of 60 cases of pulmonary pleomorphic carcinoma identified between 1999 and 2011 were studied. Of these, 55 patients had peripheral disease and five had central disease. The tumor size in all patients was 1-9.5 cm (mean, 5.8 ± 4.5 cm), while 30 had lesions with a diameter larger than 5 cm. All patients underwent pulmonary resection.
RESULTS: There were no in-hospital deaths. The three and five year survival rates of all patients were 47.2% and 25.6%, respectively. The three and five year survival rates were 57.3% and 32.5% for N0 patients, and 25.4% and 17.1% for N1-2 patients, respectively. Overall survival was significantly different between the radical resection and incomplete resection groups. Multivariate Cox regression analyses of overall survival for all 60 patients indicated that radical resection (P= 0.041), tumor node metastasis (TNM) stage (P= 0.044), and nodal status (P= 0.029) were significant independent prognostic factors.
CONCLUSION: Pleomorphic carcinoma is a rare type of lung cancer. In our study, pleomorphic carcinoma of the lung was often found as a peripherally located large mass and was associated with a poor prognosis. Radical resection, TNM stage and nodal status were significant independent prognostic factors.

Entities:  

Keywords:  Lung cancer surgery; pulmonary pleomorphic carcinoma; retrospective study; surgical treatment; thoracotomy

Year:  2014        PMID: 26767008      PMCID: PMC4704310          DOI: 10.1111/1759-7714.12086

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


  11 in total

1.  Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma.

Authors:  Y L Chang; Y C Lee; J Y Shih; C T Wu
Journal:  Lung Cancer       Date:  2001-10       Impact factor: 5.705

2.  CT findings of surgically resected pleomorphic carcinoma of the lung in 30 patients.

Authors:  Tae Sung Kim; Joungho Han; Kyung Soo Lee; Yeon Joo Jeong; Seo Hyun Kwak; Hong Sik Byun; Myung Jin Chung; Hojoong Kim; O Jung Kwon
Journal:  AJR Am J Roentgenol       Date:  2005-07       Impact factor: 3.959

3.  Clinicopathological characteristics of surgically resected pulmonary pleomorphic carcinoma.

Authors:  Fengshi Chen; Makoto Sonobe; Toshihiko Sato; Hiroaki Sakai; Cheng-Long Huang; Toru Bando; Hiroshi Date
Journal:  Eur J Cardiothorac Surg       Date:  2012-01-06       Impact factor: 4.191

4.  Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases.

Authors:  Giulio Rossi; Alberto Cavazza; Nathalie Sturm; Mario Migaldi; Nicola Facciolongo; Lucia Longo; Antonio Maiorana; Elisabeth Brambilla
Journal:  Am J Surg Pathol       Date:  2003-03       Impact factor: 6.394

5.  Palliative chemotherapy for pulmonary pleomorphic carcinoma.

Authors:  Hyun-Mi Bae; Hye Sook Min; Se-Hoon Lee; Dong-Wan Kim; Doo Hyun Chung; Jong-Seok Lee; Young Whan Kim; Dae Seog Heo
Journal:  Lung Cancer       Date:  2007-06-18       Impact factor: 5.705

6.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

7.  Pleomorphic carcinoma of the lung: clinicopathologic characteristics of 70 cases.

Authors:  Takahiro Mochizuki; Genichiro Ishii; Kanji Nagai; Junji Yoshida; Mitsuyo Nishimura; Tetsuya Mizuno; Tomoyuki Yokose; Kazuya Suzuki; Atsushi Ochiai
Journal:  Am J Surg Pathol       Date:  2008-11       Impact factor: 6.394

8.  Clinical characteristics of pleomorphic carcinoma of the lung.

Authors:  Kenichiro Ito; Satoshi Oizumi; Shinichi Fukumoto; Masao Harada; Takashi Ishida; Yuka Fujita; Toshiyuki Harada; Tetsuya Kojima; Hiroshi Yokouchi; Masaharu Nishimura
Journal:  Lung Cancer       Date:  2009-07-03       Impact factor: 5.705

9.  Pleomorphic carcinoma of the lung: a surgical outcome.

Authors:  Tsuyoshi Yuki; Toshiko Sakuma; Chiho Ohbayashi; Masahiro Yoshimura; Noriaki Tsubota; Yutaka Okita; Morihito Okada
Journal:  J Thorac Cardiovasc Surg       Date:  2007-08       Impact factor: 5.209

10.  Clinicopathological investigation of pulmonary pleomorphic carcinoma.

Authors:  Satoshi Yamamoto; Daisuke Hamatake; Takao Ueno; Takao Higuchi; Masahumi Hiratsuka; Takeshi Shiraishi; Akinori Iwasaki; Takayuki Shirakusa
Journal:  Eur J Cardiothorac Surg       Date:  2007-10-17       Impact factor: 4.191

View more
  2 in total

1.  Ringed fluorodeoxyglucose uptake predicted poor prognosis after resection of pulmonary pleomorphic carcinoma.

Authors:  Yutaka Shishido; Akihiro Aoyama; Shigeo Hara; Yuki Sato; Keisuke Tomii; Hiroshi Hamakawa; Yutaka Takahashi
Journal:  J Cardiothorac Surg       Date:  2022-03-21       Impact factor: 1.637

2.  Clinicopathological characteristics, survival outcomes and prognostic factors in pleomorphic carcinoma: a SEER population-based study.

Authors:  Zhongzhong Chen; Jiachang Liu; Lingfeng Min
Journal:  BMC Pulm Med       Date:  2022-03-31       Impact factor: 3.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.